Who Owns Protagonist Therapeutics Stock?
NASDAQ: PTGXHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Ownership breakdown
- Held by institutions
- 119.69%
- Institutions (% of float)
- 120.54%
- Held by insiders
- 0.71%
- Institutional holders
- 488
- Institutions 99.3%
- Insiders 0.7%
- Public and other 0.0%
Who owns Protagonist Therapeutics stock?
Institutional investors own about 119.7% of Protagonist Therapeutics's shares, spread across 488 institutions that file 13F reports. That level of institutional ownership is high, typical of large, widely followed companies. Insiders, including executives, directors and large founding shareholders, hold 0.71% of PTGX.
The largest institutional holders are Blackrock Inc. (15.93%), Farallon Capital Management LLC (9.81%) and RTW Investments LP (7.82%). Together, the top 10 institutions control 66.6% of shares outstanding. In their latest filings, 6 of the top 10 institutions increased their PTGX positions and 2 reduced them.
Summary generated from market data by MetaCap's automated system. Methodology
Top institutional holders of PTGX
| Institution | Shares | % Held | Change |
|---|---|---|---|
| Blackrock Inc. | 10.31M | 15.93% | +5.4% |
| Farallon Capital Management LLC | 6.35M | 9.81% | 0.0% |
| RTW Investments LP | 5.06M | 7.82% | +0.0% |
| Vanguard Portfolio Management LLC | 3.63M | 5.61% | +4.3% |
| Wellington Management Group, LLP | 3.42M | 5.28% | -5.1% |
| UBS Group AG | 3.40M | 5.25% | -34.4% |
| State Street Corporation | 3.32M | 5.13% | +6.6% |
| Vanguard Capital Management LLC | 2.85M | 4.41% | +1.7% |
| Johnson & Johnson | 2.45M | 3.78% | 0.0% |
| Invesco Ltd. | 2.34M | 3.62% | +8.1% |
% held is the share of total shares outstanding. Change is the percentage change in the position since the holder's previous 13F filing.
Top mutual fund and ETF holders of PTGX
| Fund | Shares | % Held |
|---|---|---|
| iShares Trust-iShares Core S&P Small-Cap ETF | 3.68M | 5.69% |
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 2.04M | 3.16% |
| iShares Trust-iShares Russell 2000 ETF | 1.57M | 2.42% |
| VANGUARD INDEX FUNDS-Vanguard Small-Cap Index Fund | 1.48M | 2.28% |
| VANGUARD SPECIALIZED FUNDS-Vanguard Health Care Fund | 1.24M | 1.92% |
| SPDR SERIES TRUST-State Street SPDR S&P Biotech ETF | 992.05K | 1.53% |
| Vanguard Explorer Fund | 881.16K | 1.36% |
| VANGUARD INDEX FUNDS-Vanguard Small-Cap Growth Index Fund | 849.90K | 1.31% |
| T. Rowe Price Health Sciences Fund, Inc. | 828.56K | 1.28% |
| AIM Counselor Series TRT -Invesco Discovery Fd. | 810.09K | 1.25% |
Frequently asked questions
Who is the largest shareholder of Protagonist Therapeutics?
Blackrock Inc. is the largest institutional shareholder of PTGX, owning 15.93% of shares outstanding (10.31M shares) as of its latest 13F filing.
What percentage of Protagonist Therapeutics is owned by institutions?
Institutions own about 119.7% of PTGX shares and 120.5% of the public float.
How much of Protagonist Therapeutics do insiders own?
Insiders, such as officers and directors, own about 0.71% of PTGX shares outstanding.
Where does institutional ownership data come from?
Investment managers with more than $100 million in US equities must file Form 13F with the SEC within 45 days of each quarter-end. Holdings are therefore up to about 4.5 months old when published.